Dynamic pattern of postprandial bile acids in paediatric non‐alcoholic fatty liver disease
Background Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non‐alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study,...
Saved in:
Published in | Liver international Vol. 44; no. 10; pp. 2793 - 2806 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.10.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 1478-3223 1478-3231 1478-3231 |
DOI | 10.1111/liv.16054 |
Cover
Abstract | Background
Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non‐alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD.
Methods
We recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7‐hydroxy‐4‐cholesten‐3‐one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT.
Findings
Conjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine‐conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine‐conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and −.233, p < .05), insulin (r = .327 and −.236, p < .05) and c‐peptide (r = .318 and −.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity.
Interpretation
This study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD. |
---|---|
AbstractList | Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non-alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD.BACKGROUNDDysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non-alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD.We recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT.METHODSWe recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT.Conjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine-conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine-conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and -.233, p < .05), insulin (r = .327 and -.236, p < .05) and c-peptide (r = .318 and -.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity.FINDINGSConjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine-conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine-conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and -.233, p < .05), insulin (r = .327 and -.236, p < .05) and c-peptide (r = .318 and -.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity.This study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD.INTERPRETATIONThis study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD. BackgroundDysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non‐alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD.MethodsWe recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7‐hydroxy‐4‐cholesten‐3‐one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT.FindingsConjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine‐conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine‐conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and −.233, p < .05), insulin (r = .327 and −.236, p < .05) and c‐peptide (r = .318 and −.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity.InterpretationThis study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD. Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non-alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD. We recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT. Conjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine-conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine-conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and -.233, p < .05), insulin (r = .327 and -.236, p < .05) and c-peptide (r = .318 and -.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity. This study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD. Background Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non‐alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD. Methods We recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7‐hydroxy‐4‐cholesten‐3‐one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT. Findings Conjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine‐conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine‐conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and −.233, p < .05), insulin (r = .327 and −.236, p < .05) and c‐peptide (r = .318 and −.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity. Interpretation This study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD. |
Author | Alisi, Anna Shao, Jie Loomba, Rohit Wu, Wei Xiang, Wenqin Xu, Cuifang Fu, Junfen Zheng, Ming‐Hua Dong, Guanping Ni, Yan Lin, Hu Huang, Jiating Liu, A‐Na |
AuthorAffiliation | 1 Department of Endocrinology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China 4 Department of Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China 6 MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 3 NAFLD Research Center, Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA 5 Department of Child Healthcare, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China 2 Research Unit of Genetics of Complex Phenotypes, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy |
AuthorAffiliation_xml | – name: 4 Department of Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China – name: 3 NAFLD Research Center, Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA – name: 1 Department of Endocrinology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China – name: 5 Department of Child Healthcare, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China – name: 2 Research Unit of Genetics of Complex Phenotypes, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy – name: 6 MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China |
Author_xml | – sequence: 1 givenname: Jiating surname: Huang fullname: Huang, Jiating organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 2 givenname: Hu surname: Lin fullname: Lin, Hu organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 3 givenname: A‐Na surname: Liu fullname: Liu, A‐Na organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 4 givenname: Wei surname: Wu fullname: Wu, Wei organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 5 givenname: Anna orcidid: 0000-0001-7241-6329 surname: Alisi fullname: Alisi, Anna organization: Bambino Gesù Children's Hospital, IRCCS – sequence: 6 givenname: Rohit orcidid: 0000-0002-4845-9991 surname: Loomba fullname: Loomba, Rohit organization: University of California, San Diego – sequence: 7 givenname: Cuifang surname: Xu fullname: Xu, Cuifang organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 8 givenname: Wenqin surname: Xiang fullname: Xiang, Wenqin organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 9 givenname: Jie surname: Shao fullname: Shao, Jie organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 10 givenname: Guanping surname: Dong fullname: Dong, Guanping organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 11 givenname: Ming‐Hua orcidid: 0000-0003-4984-2631 surname: Zheng fullname: Zheng, Ming‐Hua email: zhengmh@wmu.edu.cn organization: the First Affiliated Hospital of Wenzhou Medical University – sequence: 12 givenname: Junfen surname: Fu fullname: Fu, Junfen email: fjf68@zju.edu.cn organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health – sequence: 13 givenname: Yan orcidid: 0000-0003-1779-7266 surname: Ni fullname: Ni, Yan email: yanni617@zju.edu.cn organization: Zhejiang University School of Medicine, National Clinical Research Center for Child Health |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39082260$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uc1OVDEYbQxGYHTBC5ibuJHFQH_uX1fGICDJJG7AlUnzTfsVSjrttb2DmZ2P4DPyJHScgSjRbvp3zsn5ztknOyEGJOSA0SNW1rF3d0espU39guyxuuunggu283TmYpfs53xLKZOyYa_IrpC057yle-Tbp1WAhdPVAOOIKVTRVkPM45AgGAe-mjuPFWhncuVCQWF5HVMhFA_3P3-B1_Em-nK3RWBVFSuYKuMyQsbX5KUFn_HNdp-Qq7PTy5PP09mX84uTj7Oprqmspy3Oa2yltca0XSNbg5pzJrFmVPRSamY1a9rGllF5Z9Aa6DqK0IGFrgYjxYR82OgOy_kCjcYwJvBqSG4BaaUiOPX3T3A36jreKcaFXOdTFN5vFVL8vsQ8qoXLGr2HgHGZlaB9K3pOS7AT8u4Z9DYuUyjzKcFYLVgnZF9Qb_-09OTlMfkCON4AdIo5J7RKuxFGF9cOnVeMqnW3qgSqfndbGIfPGI-i_8Ju1X-U-lb_B6rZxdcN4wEi87Vs |
CitedBy_id | crossref_primary_10_3390_ijms252313190 |
Cites_doi | 10.1002/mnfr.202200636 10.2337/diacare.27.6.1487 10.1099/00207713-50-3-971 10.1155/2021/6613827 10.1038/nchembio.1864 10.1124/dmd.108.022194 10.2471/BLT.07.043497 10.1152/ajpendo.90748.2008 10.1152/ajpgi.00476.2020 10.1002/hep.32568 10.1016/j.tem.2024.02.007 10.1016/j.cell.2024.03.034 10.1136/gutjnl-2017-314307 10.1021/acs.molpharmaceut.8b00159 10.1097/MPG.0000000000000774 10.1016/j.metabol.2010.03.006 10.1007/BF01062108 10.1016/j.ebiom.2021.103290 10.1016/j.medj.2024.03.017 10.3389/fped.2022.917714 10.1002/hep.29251 10.1126/science.284.5418.1365 10.1111/apt.17362 10.1016/j.cmet.2005.09.001 10.1038/s41467-021-21744-w 10.1002/hep.29359 10.1038/s41575-023-00846-4 10.1136/gutjnl-2012-303867 10.1016/j.jnutbio.2023.109434 10.1111/liv.14802 10.1177/0004563212473450 10.1002/hep.510240121 10.1111/j.1651-2227.2007.00399.x 10.1016/j.cell.2021.04.015 10.1186/s12876-018-0805-z 10.1016/j.cmet.2023.07.011 10.1210/jc.2016-1607 10.1007/s10620-015-3776-8 10.1172/JCI111809 10.1002/hep.31603 10.1016/S2468-1253(22)00165-0 10.1016/j.cmet.2020.11.017 10.1038/s41575-020-00381-6 10.2337/dc21-1023 10.1111/apt.15035 10.1038/s42255-022-00559-z 10.1152/ajpgi.00157.2017 10.1016/j.plipres.2022.101210 10.1016/j.anaerobe.2009.05.004 10.1111/dom.14683 10.1016/j.chemphyslip.2011.05.003 10.1002/hep.28016 10.1111/j.1365-2796.2006.01731.x 10.1038/s41401-022-00880-z 10.1038/s41575-021-00566-7 10.1016/j.metabol.2019.154042 |
ContentType | Journal Article |
Copyright | 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2024 John Wiley & Sons A/S |
Copyright_xml | – notice: 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2024 John Wiley & Sons A/S |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 5PM |
DOI | 10.1111/liv.16054 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Genetics Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1478-3231 |
EndPage | 2806 |
ExternalDocumentID | PMC12393223 39082260 10_1111_liv_16054 LIV16054 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: Key Research & Development Program of Zhejiang funderid: 2023C03047 – fundername: National Natural Science Foundation of China funderid: 82170583; 81900510 – fundername: NIAAA funderid: U01AA029019 – fundername: NCATS funderid: 5UL1TR001442 – fundername: NIDDK funderid: U01DK061734; U01DK130190; R01DK106419; R01DK121378; R01DK124318; P30DK120515 – fundername: National Key Research and Development Program of China funderid: 2021YFC2701904; 2021YFC2701901 – fundername: NHLBI funderid: P01HL147835 – fundername: NIDDK NIH HHS grantid: R01 DK121378 – fundername: NIDDK NIH HHS grantid: P30 DK120515 – fundername: NIDDK NIH HHS grantid: R01 DK124318 – fundername: Key Research & Development Program of Zhejiang grantid: 2023C03047 – fundername: NIDDK NIH HHS grantid: R01DK121378 – fundername: NIDDK NIH HHS grantid: R01DK124318 – fundername: NHLBI NIH HHS grantid: P01HL147835 – fundername: NCATS NIH HHS grantid: UL1 TR001442 – fundername: NIDDK NIH HHS grantid: U01 DK130190 – fundername: NIDDK NIH HHS grantid: U01DK130190 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION 1OB AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c4094-6eb4e69ffdd67596dec2219e4103899c1fc1565f11127defda770ea7afa74ad93 |
IEDL.DBID | DR2 |
ISSN | 1478-3223 1478-3231 |
IngestDate | Sat Aug 30 05:11:24 EDT 2025 Fri Sep 05 10:19:29 EDT 2025 Wed Aug 13 10:43:46 EDT 2025 Mon Sep 01 01:54:26 EDT 2025 Tue Jul 01 04:10:12 EDT 2025 Thu Apr 24 23:03:58 EDT 2025 Wed Jan 22 17:14:04 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | blunted response oral glucose tolerance test dynamic pattern bile acids non‐alcoholic fatty liver disease |
Language | English |
License | 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4094-6eb4e69ffdd67596dec2219e4103899c1fc1565f11127defda770ea7afa74ad93 |
Notes | Handling Editor Jiating Huang, Hu Lin and A‐Na Liu contributed equally to this work. Dr. Luca Valenti ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Jiating Huang: Methodology; formal analysis; visualization; writing—original draft preparation; writing—review and editing. Hu Lin: Methodology; investigation; data curation. A-Na Liu: Methodology; investigation; data curation. Wei Wu: Methodology; investigation; data curation. Anna Alisi: Methodology; formal analysis; writing—review and editing. Rohit Loomba: Methodology; formal analysis; writing—review and editing. Cuifang Xu: Methodology; data curation; formal analysis; visualization. Wenqin Xiang: Methodology; investigation; data curation. Jie Shao: Methodology; investigation; data curation. Guanping Dong: Methodology; investigation; data curation. Ming-Hua Zheng: Methodology; investigation; writing—original draft preparation. Junfen Fu: investigation; supervision; project administration. Yan Ni: Conceptualization; methodology; writing—original draft preparation; writing—review and editing; supervision; project administration; funding acquisition. AUTHOR CONTRIBUTIONS Jiating Huang, Hu Lin and A-Na Liu contributed equally to this work. |
ORCID | 0000-0003-4984-2631 0000-0003-1779-7266 0000-0002-4845-9991 0000-0001-7241-6329 |
PMID | 39082260 |
PQID | 3114317398 |
PQPubID | 2045125 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_12393223 proquest_miscellaneous_3086382032 proquest_journals_3114317398 pubmed_primary_39082260 crossref_citationtrail_10_1111_liv_16054 crossref_primary_10_1111_liv_16054 wiley_primary_10_1111_liv_16054_LIV16054 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2024 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Liver international |
PublicationTitleAlternate | Liver Int |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2023; 35 2010; 16 2021; 66 2021; 321 2004; 27 2011; 60 2013; 62 2000; 50 2008; 36 2016; 101 2022; 24 2024; 187 1999; 284 2024 2021; 73 2017; 313 1978; 6 2023; 67 2021; 33 2024; 5 2013; 50 2024; 21 2022; 76 1996; 24 2018; 33 2021; 41 2021; 2021 2011; 164 2023; 57 2017; 66 2015; 11 2023; 121 2022; 45 2021; 184 2022; 43 2007; 96 2009; 296 2020; 103 2018; 67 2018; 18 2021; 12 2023; 89 2015; 60 2022; 4 2015; 62 2015; 61 2021; 18 2022; 7 2019; 49 2022; 10 2006; 260 2007; 85 2005; 2 1985; 75 2018; 15 2022; 19 e_1_2_12_4_1 e_1_2_12_6_1 e_1_2_12_19_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_38_1 e_1_2_12_20_1 e_1_2_12_22_1 e_1_2_12_43_1 e_1_2_12_24_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_47_1 e_1_2_12_28_1 e_1_2_12_49_1 e_1_2_12_31_1 e_1_2_12_52_1 e_1_2_12_33_1 e_1_2_12_54_1 e_1_2_12_35_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_58_1 e_1_2_12_14_1 e_1_2_12_12_1 e_1_2_12_8_1 e_1_2_12_10_1 e_1_2_12_50_1 e_1_2_12_3_1 e_1_2_12_5_1 e_1_2_12_18_1 e_1_2_12_16_1 e_1_2_12_39_1 e_1_2_12_42_1 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_40_1 e_1_2_12_27_1 Chinese Pediatric Society (e_1_2_12_41_1) 2018; 33 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_53_1 e_1_2_12_32_1 e_1_2_12_55_1 e_1_2_12_34_1 e_1_2_12_57_1 e_1_2_12_36_1 e_1_2_12_15_1 e_1_2_12_13_1 e_1_2_12_11_1 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_9_1 |
References_xml | – volume: 321 start-page: G55 issue: 1 year: 2021 end-page: G66 article-title: Dynamics of the enterohepatic circulation of bile acids in healthy humans publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 27 start-page: 1487 issue: 6 year: 2004 end-page: 1495 article-title: Use and abuse of HOMA modeling publication-title: Diabetes Care – volume: 18 start-page: 76 issue: 1 year: 2018 article-title: Response of fibroblast growth factor 19 and bile acid synthesis after a body weight‐adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non‐randomized controlled pilot trial publication-title: BMC Gastroenterol – volume: 67 start-page: 534 issue: 2 year: 2018 end-page: 548 article-title: The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids publication-title: Hepatology – volume: 11 start-page: 685 issue: 9 year: 2015 end-page: 690 article-title: A biosynthetic pathway for a prominent class of microbiota‐derived bile acids publication-title: Nat Chem Biol – volume: 62 start-page: 654 issue: 4 year: 2013 end-page: 655 article-title: Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile‐acid dysmetabolism and gut inflammation in inflammatory bowel disease publication-title: Gut – volume: 89 year: 2023 article-title: Bile acids and their receptors in regulation of gut health and diseases publication-title: Prog Lipid Res – volume: 61 start-page: 85 issue: 1 year: 2015 end-page: 90 article-title: Serum bile acid levels in children with nonalcoholic fatty liver disease publication-title: J Pediatr Gastroenterol Nutr – volume: 96 start-page: 1209 issue: 8 year: 2007 end-page: 1213 article-title: Nonalcoholic fatty liver disease in overweight children and adolescents publication-title: Acta Paediatr – volume: 35 start-page: 1752 issue: 10 year: 2023 end-page: 1766 article-title: Hyodeoxycholic acid alleviates non‐alcoholic fatty liver disease through modulating the gut‐liver axis publication-title: Cell Metab – volume: 121 year: 2023 article-title: The chronic consumption of dietary fructose promotes the gut clostridium species imbalance and bile acid alterations in developing nonalcoholic fatty liver disease publication-title: J Nutr Biochem – volume: 60 start-page: 404 issue: 3 year: 2011 end-page: 413 article-title: Plasma metabolomic profile in nonalcoholic fatty liver disease publication-title: Metabolism – volume: 66 start-page: 1631 issue: 5 year: 2017 end-page: 1643 article-title: Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice publication-title: Hepatology – volume: 103 year: 2020 article-title: Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes publication-title: Metabolism – volume: 60 start-page: 3318 issue: 11 year: 2015 end-page: 3328 article-title: Altered bile acid metabolome in patients with nonalcoholic Steatohepatitis publication-title: Dig Dis Sci – volume: 50 start-page: 360 issue: Pt 4 year: 2013 end-page: 364 article-title: Higher circulating bile acid concentrations in obese patients with type 2 diabetes publication-title: Ann Clin Biochem – volume: 21 start-page: 46 issue: 1 year: 2024 end-page: 56 article-title: Recompensation in cirrhosis: unravelling the evolving nature history of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol – volume: 43 start-page: 1103 issue: 5 year: 2022 end-page: 1119 article-title: Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease publication-title: Acta Pharmacol Sin – volume: 15 start-page: 2621 issue: 7 year: 2018 end-page: 2632 article-title: Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver publication-title: Mol Pharm – volume: 187 start-page: 2717 issue: 11 year: 2024 end-page: 2734 e2733 article-title: Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway publication-title: Cell – volume: 67 issue: 11 year: 2023 article-title: Bile acid alterations characterize the early onset and progression of nonalcoholic fatty liver disease in young mice fed with high fat and fructose diet publication-title: Mol Nutr Food Res – volume: 33 start-page: 791 issue: 4 year: 2021 end-page: 803 e797 article-title: Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism publication-title: Cell Metab – volume: 41 start-page: 894 issue: 5 year: 2021 end-page: 904 article-title: Fibroblast growth factor 19: potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease publication-title: Liver Int – volume: 62 start-page: 1576 issue: 5 year: 2015 end-page: 1583 article-title: Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease publication-title: Hepatology – volume: 18 start-page: 223 issue: 4 year: 2021 end-page: 238 article-title: Global epidemiology of NAFLD‐related HCC: trends, predictions, risk factors and prevention publication-title: Nat Rev Gastroenterol Hepatol – volume: 57 start-page: 872 issue: 8 year: 2023 end-page: 885 article-title: Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease publication-title: Aliment Pharmacol Ther – volume: 164 start-page: 525 issue: 6 year: 2011 end-page: 529 article-title: Bile acid signaling after an oral glucose tolerance test publication-title: Chem Phys Lipids – volume: 45 start-page: 425 issue: 2 year: 2022 end-page: 435 article-title: Impaired insulin clearance as the initial regulator of obesity‐associated hyperinsulinemia: novel insight into the underlying mechanism based on serum bile acid profiles publication-title: Diabetes Care – volume: 73 start-page: 2546 issue: 6 year: 2021 end-page: 2563 article-title: Application of artificial intelligence for the diagnosis and treatment of liver diseases publication-title: Hepatology – volume: 50 start-page: 971 issue: Pt 3 year: 2000 end-page: 978 article-title: Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha‐dehydroxylating activity to and proposal of sp. nov., isolated from human faeces publication-title: Int J Syst Evol Microbiol – volume: 76 start-page: 1811 issue: 6 year: 2022 end-page: 1824 article-title: Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD publication-title: Hepatology – volume: 7 start-page: 851 issue: 9 year: 2022 end-page: 861 article-title: The prevalence and incidence of NAFLD worldwide: a systematic review and meta‐analysis publication-title: Lancet Gastroenterol Hepatol – volume: 101 start-page: 3002 issue: 8 year: 2016 end-page: 3009 article-title: Postprandial plasma concentrations of individual bile acids and FGF‐19 in patients with type 2 diabetes publication-title: J Clin Endocrinol Metab – volume: 2021 year: 2021 article-title: NAFLD, insulin resistance, and diabetes mellitus type 2 publication-title: Can J Gastroenterol Hepatol – volume: 19 start-page: 432 issue: 7 year: 2022 end-page: 450 article-title: Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology publication-title: Nat Rev Gastroenterol Hepatol – volume: 2 start-page: 217 issue: 4 year: 2005 end-page: 225 article-title: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis publication-title: Cell Metab – volume: 33 start-page: 487 issue: 7 year: 2018 end-page: 492 article-title: Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children publication-title: Chin J Pract Pediatr – volume: 5 start-page: 797 issue: 7 year: 2024 end-page: 815.e2 article-title: An international multidisciplinary consensus on pediatric metabolic dysfunction‐associated fatty liver disease publication-title: Med – volume: 4 start-page: 416 issue: 4 year: 2022 end-page: 423 article-title: Metabolic messengers: bile acids publication-title: Nat Metab – volume: 75 start-page: 1144 issue: 4 year: 1985 end-page: 1152 article-title: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction publication-title: J Clin Invest – volume: 260 start-page: 530 issue: 6 year: 2006 end-page: 536 article-title: Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man publication-title: J Intern Med – volume: 36 start-page: 1983 issue: 10 year: 2008 end-page: 1991 article-title: Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid publication-title: Drug Metab Dispos – volume: 66 year: 2021 article-title: Conjugated secondary 12alpha‐hydroxylated bile acids promote liver fibrogenesis publication-title: EBioMedicine – volume: 6 start-page: 539 issue: 6 year: 1978 end-page: 546 article-title: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve publication-title: J Pharmacokinet Biopharm – volume: 313 start-page: G300 issue: 4 year: 2017 end-page: G312 article-title: Determinants of postprandial plasma bile acid kinetics in human volunteers publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 284 start-page: 1365 issue: 5418 year: 1999 end-page: 1368 article-title: Bile acids: natural ligands for an orphan nuclear receptor publication-title: Science – volume: 67 start-page: 1881 issue: 10 year: 2018 end-page: 1891 article-title: Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD publication-title: Gut – volume: 296 start-page: E384 issue: 2 year: 2009 end-page: E393 article-title: Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? publication-title: Am J Physiol Endocrinol Metab – volume: 16 start-page: 137 issue: 2 year: 2010 end-page: 146 article-title: Isolation and characterization of a bile acid inducible 7alpha‐dehydroxylating operon in TN271 publication-title: Anaerobe – volume: 10 year: 2022 article-title: Higher levels of plasma hyaluronic acid and N‐terminal Propeptide of type III procollagen are associated with lower kidney function in children with non‐alcoholic fatty liver disease publication-title: Front Pediatr – volume: 12 issue: 1 year: 2021 article-title: Hyocholic acid species as novel biomarkers for metabolic disorders publication-title: Nat Commun – year: 2024 article-title: Current status and future trends of the global burden of MASLD publication-title: Trends Endocrinol Metab – volume: 85 start-page: 660 issue: 9 year: 2007 end-page: 667 article-title: Development of a WHO growth reference for school‐aged children and adolescents publication-title: Bull World Health Organ – volume: 24 start-page: 123 issue: 1 year: 1996 end-page: 126 article-title: Serum concentrations of 7alpha‐hydroxy‐4‐cholesten‐3‐one reflect bile acid synthesis in humans publication-title: Hepatology – volume: 49 start-page: 183 issue: 2 year: 2019 end-page: 193 article-title: Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose‐dependent changes with increase in fibrosis stage in patients with biopsy‐proven NAFLD publication-title: Aliment Pharmacol Ther – volume: 184 start-page: 2537 issue: 10 year: 2021 end-page: 2564 article-title: Mechanisms and disease consequences of nonalcoholic fatty liver disease publication-title: Cell – volume: 24 start-page: 1132 issue: 6 year: 2022 end-page: 1142 article-title: Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2‐hour plasma glucose in individuals without diabetes publication-title: Diabetes Obes Metab – ident: e_1_2_12_10_1 doi: 10.1002/mnfr.202200636 – ident: e_1_2_12_36_1 doi: 10.2337/diacare.27.6.1487 – ident: e_1_2_12_47_1 doi: 10.1099/00207713-50-3-971 – ident: e_1_2_12_7_1 doi: 10.1155/2021/6613827 – ident: e_1_2_12_50_1 doi: 10.1038/nchembio.1864 – ident: e_1_2_12_54_1 doi: 10.1124/dmd.108.022194 – ident: e_1_2_12_34_1 doi: 10.2471/BLT.07.043497 – ident: e_1_2_12_29_1 doi: 10.1152/ajpendo.90748.2008 – ident: e_1_2_12_12_1 doi: 10.1152/ajpgi.00476.2020 – ident: e_1_2_12_51_1 doi: 10.1002/hep.32568 – ident: e_1_2_12_9_1 doi: 10.1016/j.tem.2024.02.007 – ident: e_1_2_12_18_1 doi: 10.1016/j.cell.2024.03.034 – ident: e_1_2_12_20_1 doi: 10.1136/gutjnl-2017-314307 – ident: e_1_2_12_55_1 doi: 10.1021/acs.molpharmaceut.8b00159 – ident: e_1_2_12_19_1 doi: 10.1097/MPG.0000000000000774 – ident: e_1_2_12_21_1 doi: 10.1016/j.metabol.2010.03.006 – ident: e_1_2_12_37_1 doi: 10.1007/BF01062108 – ident: e_1_2_12_16_1 doi: 10.1016/j.ebiom.2021.103290 – ident: e_1_2_12_4_1 doi: 10.1016/j.medj.2024.03.017 – ident: e_1_2_12_33_1 doi: 10.3389/fped.2022.917714 – ident: e_1_2_12_45_1 doi: 10.1002/hep.29251 – ident: e_1_2_12_52_1 doi: 10.1126/science.284.5418.1365 – ident: e_1_2_12_39_1 doi: 10.1111/apt.17362 – ident: e_1_2_12_42_1 doi: 10.1016/j.cmet.2005.09.001 – ident: e_1_2_12_56_1 doi: 10.1038/s41467-021-21744-w – ident: e_1_2_12_23_1 doi: 10.1002/hep.29359 – ident: e_1_2_12_3_1 doi: 10.1038/s41575-023-00846-4 – ident: e_1_2_12_49_1 doi: 10.1136/gutjnl-2012-303867 – ident: e_1_2_12_11_1 doi: 10.1016/j.jnutbio.2023.109434 – ident: e_1_2_12_31_1 doi: 10.1111/liv.14802 – ident: e_1_2_12_27_1 doi: 10.1177/0004563212473450 – ident: e_1_2_12_32_1 doi: 10.1002/hep.510240121 – ident: e_1_2_12_6_1 doi: 10.1111/j.1651-2227.2007.00399.x – ident: e_1_2_12_8_1 doi: 10.1016/j.cell.2021.04.015 – ident: e_1_2_12_22_1 doi: 10.1186/s12876-018-0805-z – ident: e_1_2_12_17_1 doi: 10.1016/j.cmet.2023.07.011 – ident: e_1_2_12_28_1 doi: 10.1210/jc.2016-1607 – ident: e_1_2_12_26_1 doi: 10.1007/s10620-015-3776-8 – ident: e_1_2_12_44_1 doi: 10.1172/JCI111809 – ident: e_1_2_12_40_1 doi: 10.1002/hep.31603 – ident: e_1_2_12_5_1 doi: 10.1016/S2468-1253(22)00165-0 – ident: e_1_2_12_57_1 doi: 10.1016/j.cmet.2020.11.017 – ident: e_1_2_12_2_1 doi: 10.1038/s41575-020-00381-6 – volume: 33 start-page: 487 issue: 7 year: 2018 ident: e_1_2_12_41_1 article-title: Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children publication-title: Chin J Pract Pediatr – ident: e_1_2_12_38_1 doi: 10.2337/dc21-1023 – ident: e_1_2_12_24_1 doi: 10.1111/apt.15035 – ident: e_1_2_12_14_1 doi: 10.1038/s42255-022-00559-z – ident: e_1_2_12_43_1 doi: 10.1152/ajpgi.00157.2017 – ident: e_1_2_12_46_1 doi: 10.1016/j.plipres.2022.101210 – ident: e_1_2_12_48_1 doi: 10.1016/j.anaerobe.2009.05.004 – ident: e_1_2_12_30_1 doi: 10.1111/dom.14683 – ident: e_1_2_12_25_1 doi: 10.1016/j.chemphyslip.2011.05.003 – ident: e_1_2_12_35_1 doi: 10.1002/hep.28016 – ident: e_1_2_12_53_1 doi: 10.1111/j.1365-2796.2006.01731.x – ident: e_1_2_12_13_1 doi: 10.1038/s41401-022-00880-z – ident: e_1_2_12_15_1 doi: 10.1038/s41575-021-00566-7 – ident: e_1_2_12_58_1 doi: 10.1016/j.metabol.2019.154042 |
SSID | ssj0019951 |
Score | 2.4367104 |
Snippet | Background
Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of... Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of... BackgroundDysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2793 |
SubjectTerms | Acids Adolescent Bile acids Bile Acids and Salts - blood Biomarkers Biomarkers - blood Blood Glucose - metabolism blunted response Case-Control Studies Chenodeoxycholic acid Child Children Cholestenones - blood Cholic acid Correlation coefficient Correlation coefficients dynamic pattern Dyslipidemia Fatty liver Female Fibroblast Growth Factors - blood Glucose Glucose metabolism Glucose tolerance Glucose Tolerance Test Glycine Growth factors Humans Lipid Metabolism Lipids Liver Liver diseases Male Metabolism Non-alcoholic Fatty Liver Disease - blood non‐alcoholic fatty liver disease Obesity oral glucose tolerance test Pediatric Obesity - blood Pediatrics Postprandial Period Taurine Therapeutic targets |
Title | Dynamic pattern of postprandial bile acids in paediatric non‐alcoholic fatty liver disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.16054 https://www.ncbi.nlm.nih.gov/pubmed/39082260 https://www.proquest.com/docview/3114317398 https://www.proquest.com/docview/3086382032 https://pubmed.ncbi.nlm.nih.gov/PMC12393223 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB6KB_Hio77ii1VEvERMk-aBJ7EWFfUgVjwIYXezi8WaFtsKevIn-Bv9Jc5sHlirIN4SMtlHMrM73-7sNwDbMuSOK7m2XRUomwjlbIEThV2PUGMQcMjQxOZcXPonLe_stn5bgYPiLEzGD1EuuJFlmPGaDJyL_hcj77SfaWmkTlygjusTb37jqqSOopPHBmx5tP2Pc2DOKkRRPOWbo3PRmIM5Hif51X81E1BzBu6KpmdxJw97w4HYk6_fWB3_2bdZmM4dU3aYadIcVFRahfnDFEH54wvbYSZU1KzBV2HyIt-Rn4e7RpbSnvUMUWfKupr1uv1B74nOy2CBAhvAuGwnfdZOUapIDcLSbvrx9s6zFL14r7GAF9ahOBGWbxstQKt5fH10YucZG2xJONH2lfCUH2mdJAhEIj9RsoZDovIcw-MnHS0RL9Y19rIWJEonPAj2FQ-45oHHk8hdhAmsXS0D87xk3xUS0ST3vUDqSItQiZDOEocSvSILdot_F8uczpyyanTiAtZgg2PzES3YKkV7GYfHT0JrhQLEuRn3YxfRIjpYWKUFm-VjNEDaVeGp6g5RBkGhG1IieguWMn0pa3EpoTwiRgvCEU0qBYjce_RJ2r43JN8OcdOh3mI_jab83vL4_PTGXKz8XXQVpmronWVRiWswMXgaqnX0rgZiw5jRJ7_9Irs |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB2xSMCFfQmrQQhxCaKNm0XiglhUlnJAgDiAIsexRUVJK9oiwYlP4Bv5EmacRZRFQtwSeRLbyYw9zx6_AViXvig5UmjbUZ6yiVDOjnCisCsBagwCDumb2JzamVu95MfXles-2MnPwqT8EMWCG1mGGa_JwGlB-pOVN-pPtDZS4f0wyNHRIOi1f16QR9HZYwO3OAUA4CyY8QpRHE_xaO9s9M3F_B4p-dmDNVPQ4Rjc5o1PI0_ut7qdaEu-fOF1_G_vxmE0803ZbqpME9CnkkmY2k0Qlz88sw1mokXNMvwkDNWyTfkpuNlPs9qzluHqTFhTs1az3Wk90pEZfGGELWBC1uM2qycolWcHYUkzeX99E2mWXrzX-IJn1qBQEZbtHE3D5eHBxV7VzpI22JKgou2qiCs30DqOEYsEbqxkGUdFxUuGyk-WtETIWNHYy7IXKx0Lz9tWwhNaeFzEgTMDA1i7mgPGebztRBIBpXC5J3WgI19FPh0n9iU6RhZs5j8vlBmjOSXWaIQ5ssEGh-YjWrBWiLZSGo-fhBZzDQgzS26HDgJG9LGwSgtWi2K0QdpYEYlqdlEGcaHjUy56C2ZThSlqcSinPIJGC_weVSoEiN-7tySp3xme7xLR06HiYj-Nqvze8vD06MpczP9ddAWGqxe1U7w_O1mAkTI6a2mQ4iIMdB67agmdrU60bGzqA9IvJto |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxNBFD7ECsGXVpNqt606FhFftjTZyV7wKRhDvCQUsdKHwDI7FwxNN0uTFOqTP6G_sb_Ec2YvJKaC-JZlT3ZmknN2vm_mzHcAXstQtDwpjOvpQLskKOcmOFG4nQg9BgmHDG1uznDkD874p_POeQ3elWdhcn2IasGNIsO-rynAM2VWgnw6uaalkQ5_AA-5j0iCENHXSjuKjh5btsVp_x8nwUJWiNJ4qq-uT0YbCHMzUXIVwNoZqL8D47LveeLJxfFykRzLn3_IOv7n4B7DdoFMWTd3pSdQ02kDmt0UWfnlDXvDbK6oXYRvQH1YbMk3YdzLa9qzzCp1pmxmWDabL7IrOjCDD0ywA0zIiZqzSYpWZW0Qls7Su1-3Iq_Ri9cGH3DDppQowop9o10463_49n7gFiUbXElE0fV1wrUfGaMUMpHIV1q28Z2oecsK-cmWkUgYOwZH2Q6UNkoEwYkWgTAi4EJF3lPYwtb1HjDO1YmXSKSTwueBNJFJQp2EdJg4lAiLHHhb_nexLPTMqazGNC55DXY4tj-iA0eVaZaLeNxndFg6QFzE8Tz2kC4iwsImHXhV3cYIpG0VkerZEm2QFXohVaJ34FnuL1UrHlWUR8roQLjmSZUBqXuv30knP6zKd4vE6dBvcZzWU_7e8_jLx-_2w_6_m76E-mmvj5ejzwfwqI1ILc9QPIStxdVSP0ektUhe2Ij6DUwmJYk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+pattern+of+postprandial+bile+acids+in+paediatric+non%E2%80%90alcoholic+fatty+liver+disease&rft.jtitle=Liver+international&rft.au=Huang%2C+Jiating&rft.au=Lin%2C+Hu&rft.au=Liu%2C+A%E2%80%90Na&rft.au=Wu%2C+Wei&rft.date=2024-10-01&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=44&rft.issue=10&rft.spage=2793&rft.epage=2806&rft_id=info:doi/10.1111%2Fliv.16054&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_liv_16054 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |